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T cells11 and undoubtedly play a role as 
sentinel cells in various tissues. Also, 
several investigators have demonstrated 
that subcapsular splenic macrophages 
can eﬀectively present antigen to B cells 
(reviewed by Martinez-Pomares and 
Gordon12). Activated macrophages have 
been regarded as important mediators of 
host tissue damage, as they can induce 
apoptosis through a variety of mecha-
nisms, but recent work has also demon-
strated that dendritic cells may express 
high levels of inducible nitric oxide syn-
thase13 and induce cell death.14
Conclusion
The work by Segerer et al.1 has carefully 
utilized various cell markers to identify 
macrophages and dendritic cells within 
normal and diseased human renal tissue 
and has demonstrated diﬀerential and 
distinctive spatial localization. The chal-
lenge for the future is to understand the 
nature and function of these various cell 
types together with the factors that lead 
to their particular localization within the 
kidney. This may generate insights into 
which cells represent the best target for 
modulating the inﬂammatory process and 
augmenting subsequent tissue repair.
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Setting the stage for acute-on-
chronic kidney injury
JW Dear1 and PST Yuen2
Acute-on-chronic kidney disease will be familiar to many 
nephrologists. Hsu et al. quantify the risk of acute-on-chronic disease 
across the stages of preexisting chronic kidney disease. Their study 
demonstrates the valuable insights that large epidemiological 
studies can bring to the field of acute kidney injury.
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Several studies have shown that the prev-
alence of chronic kidney disease (CKD) 
is increasing,1 by consensus deﬁnitions 
developed by the Kidney Disease Out-
comes Quality Initiative (K/DOQI). 
These deﬁnitions and staging of CKD 
allow researchers to compare disease 
prevalence across time and across pop-
ulations and establish links between 
CKD and other diseases.2 For example, 
it is well established that CKD is a risk 
factor for cardiovascular disease, and 
this risk is significant even with mild 
impairment of kidney function.3 Hsu 
and colleagues4 (this issue) explore the 
relationship between CKD stage and the 
risk of developing acute kidney injury 
(AKI). They demonstrate that even mild 
chronic impairment of kidney function 
signiﬁcantly increases the risk of AKI.
Patients with ‘acute-on-chronic’ kidney 
disease should be familiar to most neph-
rologists. In terms of clinical practice, 
one of the strengths of the study by Hsu 
et al.4 is the quantiﬁcation of the rela-
tionship between CKD stage and risk of 
in-hospital, dialysis-requiring, AKI. The 
authors studied a large patient group, 
adults from a Kaiser Permanente cohort 
in northern California. By deﬁnition, this 
population has health insurance, and we 
hope future studies include patients with-
out insurance. The staging of ‘baseline’ 
CKD was based on outpatient measure-
ments of serum creatinine that predated 
the index episode of AKI, a signiﬁcant 
advantage over inferring baseline cre-
atinine from in-hospital measurements. 
This strategy allows for a more inclusive 
and perhaps more accurate view of the 
acute-on-chronic population. When 
the incidence of dialysis-requiring AKI 
was compared across the CKD stages, 
the authors found that “the propensity 
to develop in-hospital acute kidney fail-
ure is another complication of chronic 
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kidney disease whose risk markedly 
increases even in the upper half of stage 3 
estimated GFR.” In addition, preexisting 
diabetes, hypertension, and proteinuria 
also signiﬁcantly increased the risk of in-
hospital, dialysis-requiring AKI.
These ﬁndings may be the tip of the ice-
berg, as the risk of non-dialysis-requiring 
AKI (a disease with a signiﬁcant mor-
bidity and mortality5) remains undeter-
mined. This increased risk of AKI across 
the stages of CKD warrants clear transla-
tion to the non-nephrology community, 
as patients with CKD are often exposed 
to potentially nephrotoxic drugs, as well 
as surgical and septic insults, and it is 
important that all clinicians recognize 
the increased risk and significance of 
an acute deterioration in kidney func-
tion. Furthermore, nephrologists should 
continue to encourage the inclusion of 
CKD patients in clinical trials rather 
than their being excluded.6 Similarly, 
given their increased risk, patients with 
CKD deserve to be included in future 
trials of AKI prevention or treatment. 
Trial inclusion will not only provide 
valuable data to guide clinical practice 
but also allow the collection of biologi-
cal samples for biomarker studies. The 
need for new biomarkers reflects the 
well-described limitations of serum 
creatinine;7 for example, in the study 
of Hsu et al.,4 creatinine cannot easily 
distinguish between the natural pro-
gression of CKD and acute-on-chronic 
disease. Biomarkers that distinguish AKI 
from chronic kidney dysfunction could 
be valuable in determining where AKI 
“starts” and CKD “ﬁnishes” (Figure 1)—a 
question that may have signiﬁcant thera-
peutic implications. Which, if any, of the 
present candidates will prove to be clini-
cally useful remains to be determined, 
but sample collection from large stud-
ies of well-characterized patients will be 
essential for biomarker development.
In comparison with CKD, if we turn 
our attention toward the deﬁnition and 
staging of AKI, then we are on the cusp 
of signiﬁcant progress. Not unreasona-
bly, Hsu et al.4 deﬁned AKI “as peak in-
patient serum creatinine greater than last 
observed preadmission outpatient serum 
creatinine by ≥50% and receipt of dialy-
sis during hospitalization.” Among neph-
rologists there is no consensus regarding 
timing of initiation of dialysis in AKI, 
and this is a continuing problem if dialy-
sis is used as an end point.8 Other stud-
ies have deﬁned AKI in multiple other 
ways, making cross-study comparisons 
diﬃcult.9 Despite this heterogeneity, it 
is clear that AKI is an important dis-
ease, as the incidence is increasing and 
the development of AKI signiﬁcantly 
increases mortality.5 The impact of AKI 
on the long-term risk of developing CKD 
and cardiovascular disease is uncertain 
and is a research priority identiﬁed by 
a recent interdisciplinary Delphi proc-
ess.8 To promote research consistency, 
the Acute Kidney Injury Network has 
described common standards for diag-
nosis and classiﬁcation of AKI,10 and the 
adoption of consistent staging in future 
epidemiological studies has the poten-
tial to galvanize research. However, 
an inherent risk of establishing stag-
ing criteria is that when new biomark-
ers are established, or when new data 
compel the reclassiﬁcation of staging 
boundaries, further changes can create 
confusion and can serve as a disincen-
tive to conduct longitudinal studies for 
fear of obsolescence. This creates some-
thing of a Catch-22, where data from 
large patient populations are needed 
to establish consensus staging criteria, 
yet staging criteria are needed to ana-
lyze the data in a standardized manner, 
especially in a longitudinal study. A bal-
ance needs to be maintained between 
these competing parameters as we itera-
tively adjust staging criteria and evaluate 
patient outcomes. For example, data and 
biological-sample collection should be as 
inclusive as possible to allow reanalysis 
of the data as staging criteria change.
The study by Hsu et al.4 provides valu-
able information on the relationship 
between CKD and AKI. Future large-
scale longitudinal studies employing and 
challenging the proposed staging crite-
ria will allow even more accurate under-
standing of risk, predict outcomes, and 
ultimately guide decision making and the 
development of new therapies.
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Figure 1 | Effect of acute kidney injury on progression of chronic kidney disease. A steady 
decline in kidney function during chronic kidney disease (CKD) may be exacerbated by an episode 
of acute kidney injury (AKI). Even in mild CKD the risk of AKI is increased, and this may accelerate 
the downward spiral toward end-stage renal disease (ESRD).
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HOming in on arteriovenous 
fistula survival
W Durante1,6 and C-C Lin2,3,4,5,6
Vascular access failure is a major clinical problem for patients on 
hemodialysis, but therapeutic approaches aimed at improving 
arteriovenous fistula (AVF) dysfunction remain elusive. Using a murine 
AVF model, Juncos et al. demonstrate for the first time that the stress 
protein heme oxygenase-1 (HO-1) is induced in AVFs and that HO-1 is a 
critical determinant of AVF survival.
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Hemodialysis vascular access failure 
is the dominant cause of morbidity in 
patients with end-stage renal disease 
and contributes substantially to the 
economic burden of this patient popu-
lation. Vascular access complications 
account for about 20% of the hospitali-
zation of hemodialysis patients in the 
United States, with an annual cost of $1 
billion.1 The native arteriovenous ﬁstula 
(AVF) is the preferred form of dialysis 
access but suﬀers from frequent failure. 
According to an analysis of the pooled 
data by the Dialysis Outcomes Quality 
Initiative committee, the primary pat-
ency of AVFs was 85% at 1 year and 75% 
at 2 years after exclusion of patients with 
primary failure, the rate of which may 
be up to 50% in some centers. The major 
cause of AVF dysfunction is neointimal 
hyperplasia leading to the develop-
ment of venous stenosis and subsequent 
thrombosis. Significantly, neointimal 
hyperplasia has also been implicated in 
the failure of AVFs to mature and accom-
modate the increased rate of blood ﬂow 
required for eﬀective dialysis. Histologi-
cally, these neointimal lesions consist 
of proliferating and migrating vascular 
smooth muscle cells (VSMCs), infil-
trating inﬂammatory cells, substantial 
amounts of extracellular matrix, and 
angiogenesis in both the adventitia and 
the intima of the lesion.2 Multiple fac-
tors are believed to contribute to the 
pathogenesis of neointimal hyperplasia 
following the creation of AVFs, includ-
ing surgical injury, hemodynamic stress, 
platelet activation, endothelial dysfunc-
tion, oxidative stress, inﬂammation, and 
uremia. Although ever more sophisti-
cated surveillance techniques can reliably 
detect subcritical and critical stenoses, 
therapeutic interventions that target this 
lesion and substantially prolong patency 
remain elusive.
Heme oxygenase-1 (HO-1) is a highly 
inducible stress protein that mediates 
important vasoprotective actions in the 
circulation.3 Pharmacological induc-
tion of HO-1 or adenovirus-mediated 
HO-1 gene delivery attenuates neointi-
mal hyperplasia in injured arteries and 
retards the development of athero-
sclerotic plaques in murine models of 
atherosclerosis, whereas inhibition of 
HO-1 activity enhances lesion formation. 
In addition, HO-1-deﬁcient mice display 
enhanced neointimal thickening follow-
ing wire-induced arterial injury, robust 
VSMC proliferation in a murine vein 
graft model, and accelerated lesion for-
mation in an atherogenic rodent model. 
Moreover, HO-1 may also regulate the 
vascular response to injury in humans, 
since a long guanine–thymidine (GT) 
dinucleotide repeat microsatellite poly-
morphism in the human HO-1 promoter 
that is linked with impaired inducibility 
is associated with susceptibility to rest-
enosis in patients undergoing percutane-
ous transluminal angioplasty or coronary 
artery stenting. Interestingly, we recently 
demonstrated that the same length poly-
morphism in the HO-1 promoter is asso-
ciated with stenosis-related AVF failure 
in Chinese hemodialysis patients.4 In 
particular, we found that long GT repeats 
((GT)n ≥ 30) in the HO-1 promoter are 
associated with a higher frequency of 
access failure and poorer patency of 
AVFs. On the basis of these ﬁndings, we 
speculated that longer GT repeats in the 
HO-1 promoter might limit gene tran-
scription and consequently offset the 
protective eﬀect of HO-1 against vascu-
lar injury.
Juncos and colleagues5 (this issue) 
now directly demonstrate for the ﬁrst 
time that HO-1 plays a critical role in 
promoting AVF survival. The authors 
took advantage of a recently developed 
murine AVF model6 that recapitulates 
the salient features of dysfunctional 
AVFs in humans, including neointima 
formation and thrombosis, to show 
